Author:
Svitich O. A.,Lavrov V. F.,Kukina P. I.,Iskandaryan A. A.,Gankovskaya L. V.,Zverev V. V.
Abstract
Vaccines for many years act as one of the most effective and successfully used medicines. Vaccines obtained by traditional methods contain in their composition live, weakened or killed microorganisms (bacteria, viruses, etc.). Now more often, modern, split, subunit, recombinant, polyvalent and some other types of vaccines are being used. The addition of adjuvants to vaccines generally increases the immune response to their administration. It was established that the formation of postvaccinal immunity begins immediately after the introduction of the vaccine, by activating the factors of innate immunity in the interaction of pathogen-associated molecular patterns (PAMPs), in vaccines, with the pathogen-recognition receptors (PRRs) of the immunocompetent cells of the recipient. It is also shown that PRRs activators, including TOLL-like receptor agonists (TLRs) and poly (I:C) polynucleotide oligomers of inosine and cytidylic acids, have the ability to substantially increase the immunogenicity of vaccines, and attempts are being made to use them creation of new types of adjuvants. Defective interfering viral particles (D-particles, DIPs) are also classed as effective stimulants of innate immunity and can also be considered promising vaccine adjuvants.
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Epidemiology
Reference58 articles.
1. Ribeiro C. M., Schijns V. E. Immunology of vaccine adjuvants. Methods Mol. Biol. 2010; 626: 1–14.
2. Eibl M. M., Wolf H. M. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy. 2015; 7: 1273–1292.
3. Glenny A. T., Barr M. The precipitation of diphtheria toxoid by potash alum. J. Pathol. Bacteriol. 1931; 34: 131–138.
4. Tong N. K. C., Beran J., Kee S. A., Miguel J. L., Sánchez C., Bayas J. M. et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005; 68: 2298–2303.
5. Baz M., Luke C. J., Cheng X., Jin H., Subbarao K. H5N1 vaccines in humans. Virus Res. 2013; 178: 78–98.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献